Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-13C6]-d-glucose tracer in mice

Metabolomics

Volumn 5, Issue 3, 2009, Pages 336-345

  Beger, Richard D ^a   Hansen, Deborah K ^a   Schnackenberg, Laura K ^a   Cross, Brandie M ^b   Fatollahi, Javad J ^b   Lagunero, F Tracy ^b   Sarnyai, Zoltan ^c   Boros, Laszlo G ^b,d  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b SiDMAP   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

U 13C6 d glucose; Stable isotope based dynamic metabolic profiling (SiDMAP); Valproic acid

Indexed keywords

MUS; RATTUS;

EID: 70149102426     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-009-0159-1     Document Type: Article

References (38)

1. Buchanan, T. A., Xiang, A., Kjos, S. L., et al. (1998). Gestational diabetes: Antepartum characteristics that predict postpartum glucose intolerance and type 2 diabetes in Latino women. Diabetes, 47, 1302-1310. doi: 10.2337/diabetes.47.8.1302.
2. Cohen, J. J., & Little, J. R. (1976). Lactate metabolism in the isolated perfused rat kidney: Relations to renal function and gluconeogenesis. The Journal of Physiology, 255, 399-414.
3. Comi, R. J., & Hamilton, H. (1994). Reduction of red cell glucose transporter intrinsic activity in diabetes running. Hormone and Metabolic Research. Hormon- und Stoffwechselforschung. Hormones et Metabolisme, 26, 26-32. doi: 10.1055/s-2007-1000767.
4. Cornford, E. M., & Oldendorf, W. H. (1986). Epilepsy and the blood-brain barrier. Advances in Neurology, 44, 787-812.
5. Crick, D. C., & Carroll, K. K. (1987). Extraction and quantitation of total cholesterol, dolichol and dolichyl phosphate from mammalian liver. Lipids, 22, 1045-1048. doi: 10.1007/BF02536448.
6. Eadie, M. J., Hooper, W. D., & Dickinson, R. G. (1988). Valproate-associated hepatotoxicity and its biochemical mechanisms. Medical Toxicology, 3(2), 85-106.
7. Espandiari, P., Zhang, J., Schnackenberg, L. K., et al. (2007). Age-related differences in susceptibility to toxic effects of valproic acid in rats. Journal of Applied Toxicology, (Nov), 9. Epub ahead of print.
8. Garg, M., Bassilian, S., Bell, C., Lee, S., & Lee, W. N. (2005). Hepatic de novo lipogenesis in stable low-birth-weight infants during exclusive breast milk feedings and during parenteral nutrition. JPEN, Journal of Parenteral and Enteral Nutrition, 29, 81-86. doi: 10.1177/ 014860710502900281.
9. Gopaul, S., Farrell, K., & Abbott, F. (2000). Gas chromatography/ negative ion chemical ionization mass spectrometry and liquid chromatography/electrospray ionization tandem mass spectrometry quantitative profiling of N-acetylcysteine conjugates of valproic acid in urine: Application in drug metabolism studies in humans. Journal of Mass Spectrometry, 35, 698-704. doi: 10.1002/ 1096-9888(200006)35:6<698::AID-JMS996>3.0.CO;2-S.
10. Gopaul, S., Farrell, K., & Abbott, F. (2003). Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. Epilepsia, 44, 322-328. doi: 10.1046/ j.1528-1157.2003.07202.x.
11. Haas, R., Stumpf, D. A., Parks, J. K., & Eguren, L. (1981). Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology, 31, 1473-1476.
12. Huang, J., Gabrielsen, J. S., Cooksey, R. C., et al. (2007). Increased glucose disposal and AMP-dependent kinase signaling in a mouse model of hemochromatosis. The Journal of Biological Chemistry, (Oct), 30. Epub ahead of print.
13. Jezequel, A. M., Bonazzi, P., Novelli, G., Venturini, C., & Orlandi, F. (1984). Early structural and functional changes in liver of rats treated with a single dose of valproic acid. Hepatology (Baltimore Md), 4, 1159-1166. doi: 10.1002/hep.1840040611.
14. 13C]glucose. Proceedings of the National Academy of Sciences of the United States of America, 88, 2103-2107. doi: 10.1073/ pnas.88.6.2103.
15. Keane, P. E., Meldrum, B. S., Simiand, J., & Vernieres, J. C. (1982). Mechanism of anticonvulsant action of valproate. Progress in Neurobiology, 19, 315-359. doi: 10.1016/0301-0082(82)90010-7.
16. Lee, W. N. (1996). Stable isotopes and mass isotopomer study of fatty acid and cholesterol synthesis, A review of the MIDA approach. Advances in Experimental Medicine and Biology, 399, 95-114.
17. Lee, W. N., Boros, L. G., Puigjaner, J., Bassilian, S., Lim, S., & Cascante, M. (1998). Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1, 2-13C2]glucose. The American Journal of Physiology, 274, E843-E851.
18. Lee, M. H., Hong, I., Kim, M., et al. (2007). Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicology and Applied Pharmacology, 220, 45-59. doi: 10.1016/ j.taap.2006.12.016.
19. Lee, W. N., Sorou, S., & Bergner, E. A. (1991). Glucose isotope, carbon recycling, and gluconeogenesis using [U-13C]glucose and mass isotopomer analysis. Biochemical Medicine and Metabolic Biology, 45, 298-309. doi: 10.1016/0885-4505(91)90034-I.
20. Lee, J. Y., Timmins, J. M., Mulya, A., et al. (2005). HDLs in apoA-I transgenic Abca1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidney. Journal of Lipid Research, 46, 2233-2245. doi: 10.1194/jlr.M500179-JLR200.
21. Lian, X. Y., Khan, F. A., & Stringer, J. L. (2007). Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats. The Journal of Neuroscience, 27, 12007-12011. doi: 10.1523/JNEUROSCI.3163-07.2007.
22. Linden, K. C., DeHaan, C. L., Zhang, Y., et al. (2006). Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. American Journal of Physiology. Renal Physiology, 290, F205-F213. doi: 10.1152/ajprenal.00237.2004.
23. Lindley, D. V. (1987). Regression and correlation analysis (Vol. 4, pp. 23-120). New Palgrave: A Dictionary of Economics.
24. Nowak, G., & Schnellmann, R. G. (1995). Improved culture conditions stimulate gluconeogenesis in primary cultures of renal proximal tubule cells. The American Journal of Physiology, 268, C1053-C1061.
25. Perucca, E. (2002). Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs, 16, 695-714. doi: 10.2165/00023210-200216100-00004.
26. Powell, N., Smith, K., & Fiander, A. (2006). Recovery of human papillomavirus nucleic acids from liquid-based cytology media. Journal of Virological Methods, 137, 58-62. doi: 10.1016/j.jviromet.2006.05.033.
27. Puchowicz, M. A., Bederman, I. R., Comte, B., et al. (1999). Zonation of acetate labeling across the liver: Implications for studies of lipogenesis by MIDA. The American Journal of Physiology, 277, E1022-E1027.
28. Sarwal, R., Sanyal, S. N., & Khera, S. (1989). Lipid metabolism in Trichuris globulosa (Nematoda). Journal of Helminthology, 63, 287-297.
29. Schnackenberg, L. K., Jones, R. C., Thyparambil, S., et al. (2006). An integrated study of acute effects of valproic acid in the liver using metabonomics, proteomics, and transcriptomics platforms. Omics, 10, 1-14. doi: 10.1089/omi.2006.10.1.
30. Silva, M. F., Ijlst, L., Allers, P., et al. (2004). Valproyl-dephosphoCoA: A novel metabolite of valproate formed in vitro in rat liver mitochondria. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 32, 1304-1310. doi: 10.1124/dmd.
31. Simon, D., & Penry, J. K. (1975). Sodium Di-N-propylacetate (DPA) in the treatment of epilepsy. Epilepsia, 16, 549-573. doi: 10.1111/ j.1528-1157.1975.tb04738.x.
32. Slatter, T. L., Jones, G. T., Williams, M. J., van Rij, A. M., & McCormick, S. P. (2008). Novel rare mutations and promoter haplotypes in ABCA1 contribute to low-HDL-C levels. Clinical Genetics, 73, 179-184. doi: 10.1111/j.1399-0004.2007.00940.x.
33. Tang, W., & Abbott, F. S. (1996). Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation, LC/MS/MS characterization of the GSH-glucuronide diconjugates. Chemical Research in Toxicology, 9, 517-526. doi: 10.1021/ tx950120y.
34. Tang, W., & Abbott, F. S. (1997). A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: Phase II metabolism and pharmacokinetics. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 25, 219-227.
35. Thurston, J. H., Hauhart, R. E., Schulz, D. W., Naccarato, E. F., Dodson, W. E., & Carroll, J. E. (1981). Chronic valproate administration produces hepatic dysfunction and may delay brain maturation in infant mice. Neurology, 31, 1063-1069.
36. Wong, H. Y., Chu, T. S., Lai, J. C., et al. (2005). Sodium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro. Journal of Cellular Biochemistry, 96, 775-785. doi: 10.1002/jcb.20555.
37. Xiao, G., Garg, M., Wong, D., Lim, S., Go, V. L. W., & Lee, W. N. (2008). Determination of protein synthesis in vivo using labeling from deuterated water and analysis of MALDI-TOF spectrum. Journal of Applied Physiology, 104, 828-836.
38. Xu, J., Lee, W. N., Xiao, G., et al. (2003). Determination of a glucose-dependent futile recycling rate constant from an intraperitoneal glucose tolerance test. Analytical Biochemistry, 315, 238-246. doi: 10.1016/S0003-2697(02)00709-1.